Objectives. This review is to inform clinicians of currently available data on vilazodone for treating patients with major depressive disorder (MDD), focusing on its diff erential action mechanism and extended clinical utility. Methods. A data search was conducted in June 2012 using the PubMed/MEDLINE/ relevant clinical trial databases with the key terms "vilazodone" or "Viibryd." Results. The effi cacy, safety, and tolerability of vilazodone have been demonstrated in two pivotal 8-week, randomized, double-blinded, placebo-controlled studies. Certain pharmacological characteristics of vilazodone were observed, including early onset of action, fewer sexual side eff ects, the absence of known cardiac toxicity, and minimal eff ect on weight gain, that may provide potential clinical advantages compared with currently available antidepressants. However, such possibilities should be replicated and confirmed in more well-designed and adequately powered clinical trials. Vilazodone requires dose titration up to 2 weeks to reach a target dose of 40 mg/d due to high rate of gastrointestinal side eff ects. No direct comparative studies with other antidepressants are currently available to confi rm the aforementioned potential clinical utility. Conclusion. Vilazodone is a newer antidepressant possessing diff erent action mechanisms compared to currently available antidepressants but whether it has superiority to other class of antidepressants in terms of effi cacy and safety should still warrant further evaluation through more well-controlled and direct comparison clinical trials.
|Number of pages||10|
|Journal||International Journal of Psychiatry in Clinical Practice|
|Publication status||Published - 2013 Aug|
- Action mechanism
- Major depressive disorder
ASJC Scopus subject areas
- Psychiatry and Mental health